News

Kenox Expands DEA-Registered Capabilities

Back

Princeton, NJ – Kenox Pharmaceuticals Inc. (Kenox) is pleased to announce that it is now DEA registered for Schedule II-V controlled substances, expanding the company’s ability to support controlled substance programs across research, development, analytical testing, and early clinical supply.

This milestone strengthens Kenox’s integrated CDMO offering for complex inhalation, intranasal, and ophthalmic drug-device products, enabling compliant support across key development and manufacturing activities, including formulation development, analytical testing and stability studies, OINDP testing, fill-finish operations, and Phase I/II clinical supply.

With this added capability, Kenox continues to advance its purpose-built CDMO platform for complex OINDP and ophthalmic products, delivering specialized expertise, integrated execution, and greater value for partners developing highly regulated therapies.

To learn how this expanded capability can help support and accelerate your program, please reach out to us at bd@kenoxpharma.us.